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Introduction
Coronary heart disease (CHD) is the leading cause of
death in the United States, accounting for more than
450,000 deaths in 2004 (1), largely because of myo-
cardial infarction and sudden cardiac death (2).
Approximately 15.8 million Americans aged 20 years
and older have CHD (1), although many individuals
are asymptomatic and go undiagnosed until the dis-
ease is in an advanced state, often after experiencing
a myocardial infarction (2). The tremendous burden
of CHD has led to the development of guidelines
and policies on prevention in the USA, encompass-
ing a larger effort to prevent and treat cardiovascular
disease (CVD), including stroke (3–6).
Because of the often asymptomatic nature of CHD
and CVD in general, assessing CVD risk factors is
usually the starting point for determining a patient’s
actual risk for CHD or CVD (7,8). Major risk factors
include tobacco smoking, high blood cholesterol,
high blood pressure, diabetes, obesity and over-
weight, physical inactivity and increasing age (2,9).
Comprehensive risk factor screening and follow-up
by a primary care provider (PCP) or other physician
are generally recommended every 2–5 years for every
adult, beginning at the age of 20 years (4,5,10,11).
More speciﬁc screening recommendations exist for
those at increased risk, such as those with type 2 dia-
betes mellitus (T2DM), who have twice the risk of
having a myocardial infarction or stroke than the
general public (4).
Although the burden of CHD is clear, screening of
risk factors and awareness of CHD and CVD in US are
less than optimal. National efforts have been under
way to promote CVD and CHD risk factor screening,
with a speciﬁc effort to achieve cholesterol screening
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What’s known
Coronary heart disease is a leading cause of death
and disability worldwide. Recent evidence-based
scientiﬁc guidelines have recommended increased
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other health conditions. More than 50% of
individuals reported that their heart disease was
diagnosed after symptoms arose.
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726 doi: 10.1111/j.1742-1241.2009.02049.xin 80% of American adults (12). According to the
Centers for Disease Control, the percentage of those
screened for high blood cholesterol in the USA
increased from 67.6% in 1991 to 73.1% in 2003 (12).
Even so, this suggests that increased awareness and
screening efforts for CVD, and CHD speciﬁcally, are
still needed. A study by Mosca et al. (13) demonstrated
that awareness of heart disease (HD) among women
has increased, although only half of women are aware
that HD is their leading cause of death. Physician
awareness and adherence to CVD and CHD guidelines
also vary. In a study by Mosca et al. (14), obstetricians
and gynaecologists, most of whom provide primary
care to their patients, were substantially less aware of
national cholesterol and blood pressure management
guidelines than PCPs or cardiologists. Physicians were
also more likely to assign lower CVD risk categories to
women who had similar calculated risks to men (14).
Thus, there appears to be multiple factors that contrib-
ute to CHD being diagnosed at later stages, when
symptoms (e.g. angina) occur.
This study was designed to determine if the self-
reported method of diagnosis of HD has changed in
recent years (since 2001) as several guidelines have
been published highlighting the need for primary and
secondary prevention. We hypothesised that routine
screening for HD would be greater in the intervals
of 2001 and later compared with 2000 and before,
because the AHA⁄ACC primary prevention guidelines
(5,6) and the National Cholesterol Education Pro-
gram (NCEP) Adult Treatment Panel (ATP) III (15)
were published in 2001–2002 and the AHA guidelines
for CVD prevention in women were published in
2004 (10). The study ﬁndings should provide insight
into whether HD is being detected through routine
screening, including risk factor screening, or whether
individuals are continuing to be diagnosed at later,
symptomatic stages.
Methods
A cross-sectional analysis of survey data from the
2006 Study to Help Improve Early evaluation and
management of risk factors Leading to Diabetes
(SHIELD) survey was conducted to determine the
method of diagnosis of HD.
SHIELD surveys
SHIELD has three phases extending over 5 years: (i)
an initial screening phase to identify cases of interest
in the general population; (ii) the baseline survey to
follow-up identiﬁed individuals with a questionnaire
about health status, health knowledge and attitudes,
and current behaviours and treatments; and (iii) four
additional annual surveys to follow disease progres-
sion in those with established diabetes as well as the
rate of transition from at risk to a diagnosis of
diabetes. The SHIELD survey methodology has been
described in detail previously (16,17).
The screening survey was mailed on 1 April 2004 to
a stratiﬁed random sample of 200,000 US households,
representative of the US population for geographic
residence, household size and income, and age of head
of household, identiﬁed by the Taylor Nelson Sofres
National Family Opinion (TNS NFO) panel. The
screening survey consisted of 12 questions designed to
identify individuals with diabetes mellitus and those
with cardiometabolic risk factors. The head of house-
hold completed the screening questionnaire for up to
four adult (aged ‡ 18 years) household members. A
response rate of 63.7% was obtained from 127,420
households (containing 211,097 adults).
The baseline survey was mailed in September and
October 2004 to a representative sample of individu-
als, independently sampled (n = 22,001), who were
identiﬁed in the screening survey as having type 1
diabetes mellitus, T2DM or one of ﬁve cardiometa-
bolic risk factors [abdominal obesity, body mass
index (BMI) ‡ 28 kg⁄m
2, diagnosis of dyslipidaemia,
diagnosis of hypertension, or history of CVD, includ-
ing HD⁄heart attack, narrow or blocked arteries,
stroke, heart bypass surgery, angioplasty or surgery
to clear arteries]. Each respondent group was bal-
anced to be representative of that population for age,
gender, geographic region, household size and
income as the US population, based on the weighted
screening data; a random sample from each group
was then selected and sent the baseline survey. A
response rate of 71.8% was obtained (n = 15,794).
Follow-up surveys
In August 2005, the ﬁrst annual follow-up survey
was mailed to all individuals selected for the baseline
survey who were still enrolled in the TNS NFO panel
(n = 19,613). The second annual follow-up survey
was mailed in July 2006 to individuals who had
returned either or both the baseline and ﬁrst annual
questionnaires (n = 18,445). A 75% response rate
was obtained for the 2006 follow-up survey
(n = 13,877). Figure 1 shows the progression of the
SHIELD surveys over time.
Risk factors
Five cardiometabolic risk factors were identiﬁed
through epidemiological studies and expert opinion
(15,18) to be associated with CHD. SHIELD respon-
dents reported their height and weight and whether
they had ever been told by a doctor that they had
cholesterol problems of any type, high blood
pressure⁄hypertension, or history of CVD (deﬁned as
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coronary artery bypass graft surgery, angioplasty⁄
stents to clear arteries). Respondents were provided
with a measuring tape and while standing were asked
to hold the tape measure loosely around their waist
at the level of their navel (belly button) to determine
waist circumference. This information was used to
deﬁne the ﬁve risk factors as: (i) abdominal obes-
ity (waist circumference: men, ‡ 97 cm; women,
‡ 89 cm), (ii) BMI ‡ 28 kg⁄m
2, (iii) reported diag-
nosis of dyslipidaemia, (iv) reported diagnosis of
hypertension, and (v) history of CVD. Other risk fac-
tors for CHD and CVD were examined among the
respondents and included smoking (current, past
and never smoked), obesity (classiﬁed underweight⁄
normal weight as BMI £ 24.9 kg⁄m
2, overweight as
BMI 25.0–29.9 kg⁄m
2, obesity as BMI ‡ 30 kg⁄m
2)
and physical activity [highly active, minimally active
and inactive based on the International Physical
Activity Questionnaire (IPAQ) (19)].
HD diagnosis
Respondents who reported HD⁄heart attack, includ-
ing angina, heart failure, angioplasty and⁄or heart
bypass surgery were identiﬁed as having HD. Indi-
viduals with HD were asked to indicate the age at
which they were diagnosed with HD. Subtracting age
at HD diagnosis from the respondent’s current age
provided estimates for the timing (year) of the HD
diagnosis. Year of HD diagnosis was categorised into
3-year intervals to capture changes before and after
the guidelines on CHD screening and prevention
(3,5,6,10,15,20). This resulted in the following eight
HD diagnosis intervals: 2004 or later, 2001–2003,
1998–2000, 1995–1997, 1992–1994, 1989–1991, 1986–
1988, or 1985 or earlier. As noted previously, because
the AHA⁄ACC primary prevention guidelines (5,6)
and the NCEP ATP III (15) were published in 2001–
2002 and the AHA guidelines for CVD prevention in
women were published in 2004 (10), it was hypo-
thesised that screening for HD would be greater in
the intervals of 2001 and later compared with 2000
and before.
Respondents who self-reported a diagnosis of HD
were also asked ‘how did you ﬁnd out that you had
HD.’ Response options included ‘during routine
screening⁄lab work (blood test, etc.) ordered by my
doctor’ (i.e. routine screening); ‘when I was tested
for it after having some health symptoms’ (i.e. symp-
toms); or ‘when I was being treated for another
health problem’ (i.e. other health problems). Respon-
dents were permitted to select multiple answers.
With these methods of diagnosis, it was determined
whether CHD and CVD screening and prevention
recommendations have led to a trend toward
increased diagnoses for HD as a result of routine
screening or whether the trend continues to reﬂect
patients being diagnosed after experiencing symp-
toms of HD or having a major CVD event. Respon-
dents were not asked about speciﬁc screening or
blood tests such as lipid levels, blood pressure or
ECG or cardiac stress tests.
Individuals were also asked to indicate the spe-
cialty of the physician who made their diagnosis (e.g.
family doctor⁄general practitioner, cardiologist or
other speciﬁed physician), as it would be important
to observe whether the promotion of guidelines has
resulted in increased screening and diagnosis by cer-
tain specialists other than cardiologists.
Statistical analyses
Respondents with HD were stratiﬁed into individuals
with and without T2DM because T2DM confers
higher risk for CHD and is considered a CHD risk
equivalent condition by NCEP ATP III (15). Com-
parisons between HD respondents with and without
T2DM were made to determine if the diagnosis of
HD was made more frequently through screening
or while being treated for another health problem
(i.e. T2DM) for respondents with T2DM. Descriptive
statistics for sociodemographic characteristics and
Screening questionnaire
Sent to 200,000 US households
127,420 households responded   
Year 2 follow-up survey (2006)
Sent to 18,445 individuals
13,877 responded  
Baseline survey
Sent to 22,001 individuals
15,794 responded  
Year 1 follow-up survey (2005)
Sent to 19,613 individuals
14,122 responded   
Figure 1 Flow of SHIELD surveys
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method and physician specialty) were provided.
Comparisons between respondents with HD and no
T2DM vs. HD with T2DM were made using chi-
square tests for proportions and t-tests for compari-
son of means. A p < 0.05 was considered statistically
signiﬁcant.
Results
There were 1573 (of 13,877) respondents from the
2006 SHIELD survey who reported a diagnosis of
HD and provided their age at time of diagnosis.
Approximately 62% (n = 973) of these HD respon-
dents did not have diabetes mellitus (i.e. type 1, type
2 or gestational diabetes), while 38% (n = 600) of
these respondents had HD and T2DM.
Demographics
In the non-diabetes group, HD respondents were
predominantly male (59.0%), white (91.3%) and of
non-Spanish heritage (99.0%) (Table 1). The respon-
dents with HD and T2DM were signiﬁcantly younger
(p = 0.0006) and fewer were men (p = 0.0002) com-
pared with the HD respondents without diabetes
(Table 1). The two groups were similar in race and
annual household income (p > 0.05).
CVD risk factors
Dyslipidaemia, hypertension and obesity were fre-
quently reported by HD respondents with and with-
out diabetes mellitus (Table 1). More than 55% of
HD respondents without diabetes mellitus and 62%
of HD respondents with T2DM were considered
obese (deﬁned as BMI ‡ 30 kg⁄m
2), while > 87% of
both groups had abdominal obesity. Signiﬁcantly
more HD respondents with T2DM were obese
(BMI ‡ 30 kg⁄m
2) than HD respondents without
diabetes mellitus (p = 0.04) (Table 1). Approximately
12% of HD respondents with and without T2DM
were current smokers. A large percentage (> 64%) of
HD respondents were physically inactive as estimated
by the IPAQ, and signiﬁcantly more HD respondents
with T2DM were inactive and fewer were highly
active compared with the HD respondents without
diabetes mellitus (p = 0.002).
Age at HD diagnosis and time since diagnosis
Mean self-reported age at HD diagnosis among
SHIELD respondents in the non-diabetes mellitus
group was 56.8 years compared with 55.8 years in
the T2DM group (p = 0.16) (Table 2). Respondents
reported that they had HD for an average of
11.7 years in the non-diabetes mellitus group and an
average of 10.7 years in the T2DM group (p = 0.06).
Approximately 31% of HD respondents without dia-
betes mellitus and 36% of HD respondents with
T2DM were diagnosed in 2001 or later (Table 2),
during the period when a number of consensus state-
ments and guidelines for screening and prevention
of CHD and CVD were published (5,6,9,10,15,20).
Between 1992 and 2000, a period during which
Table 1 Sociodemographic characteristics of SHIELD
respondents diagnosed with HD (n = 1573)
Characteristics
HD without
diabetes
(n = 973)
HD + type 2
diabetes
mellitus
(n = 600)
Gender, men, % 59.0** 49.3
Age, years, mean (SD) 69.0 (11.5)** 67.0 (11.1)
Race, %
White 91.3 87.8
Black 4.8 7.3
Other, including Asian⁄Paciﬁc
Islander, American Indian,
Eskimo, others
1.1 1.5
Spanish⁄Hispanic heritage, % 1.0 1.8
Annual household income, %
< $20,000 25.4 28.5
$20,000-$34,999 21.7 20.8
$35,000-$54,999 19.6 23.3
$55,000-$84,999 16.6 14.0
‡ $85,000 16.6 13.3
Risk factors, %
Abdominal obesity 87.2 90.4
Body mass index ‡ 28 kg⁄m
2 74.7 75.9
BMI category, %*
Underweight⁄normal
weight (BMI £ 24.9 kg⁄m
2)
14.1* 12.2
Overweight
(BMI: 25.0–29.9 kg⁄m
2)
29.9* 25.3
Obese (BMI ‡ 30 kg⁄m
2) 55.9* 62.5
Hypertension diagnosis, % 84.6 85.0
Dyslipidaemia diagnosis, % 82.4 83.7
Smoking, %
Current smoker 11.8 11.7
Past smoker 14.1 12.1
Never smoked 74.1 76.2
Physical activity§, %**
Highly active 14.9** 9.3
Minimally active 20.9** 22.3
Inactive 64.2** 68.4
*p < 0.05; **p < 0.001. 3% of each group had missing val-
ues for race. Waist circumference ‡ 97 cm for men and
‡ 89 cm for women. §International physical activity question-
naire score. HD, heart disease; SHIELD, Study to Help Improve
Early evaluation and management of risk factors Leading to
Diabetes; BMI, body mass index.
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and secondary prevention of CHD, including screen-
ing for risk factors (3,7,11), 37% of HD respondents
without diabetes mellitus and 39% of HD respon-
dents with T2DM were diagnosed. Before 1992,
31.9% of HD respondents without diabetes mellitus
and 25.1% with T2DM were diagnosed. There were
signiﬁcantly more HD respondents without diabetes
mellitus diagnosed earlier (1980s or earlier) than HD
respondents with T2DM (p = 0.01).
Diagnosing HD
In the non-diabetes mellitus group, 19.4% of indi-
viduals self-reported an HD diagnosis due to routine
screening compared with 19.5% of the T2DM group
(p = 0.99) (Table 3). However, a signiﬁcantly greater
proportion of HD respondents with T2DM reported
the diagnosis based on having symptoms (54%)
compared with respondents without diabetes mellitus
(48%) (p = 0.03). In the non-diabetes group, 14.7%
reported a diagnosis based on being treated for
another health problem compared with 22.2% of the
T2DM group (p = 0.0002) (Table 3). To determine
if the method of diagnosis changed over time, the
number of respondents reporting each method of
diagnosis (screening, symptoms or other health prob-
lem) was stratiﬁed by the time interval in which their
diagnosis of HD was made. The proportion of HD
respondents without diabetes mellitus reporting a
diagnosis based on symptoms ﬂuctuated over time,
yet the proportion reporting a diagnosis based on
routine screening or other health problem had
increased in recent years (1998 or later) but there
was no signiﬁcant trend over time (p > 0.05)
(Figure 2). For respondents with HD and T2DM, the
proportion reporting a diagnosis based on symptoms
Table 2 Age at diagnosis and year of diagnosis of HD in SHIELD respondents
Age and year of heart
disease diagnosis
HD without
diabetes (n = 973)
HD + type 2 diabetes
mellitus (n = 600)
Age at heart disease diagnosis, mean (SD) 56.8 (13.5) 55.8 (13.7)
Years with heart disease, mean (SD) 11.7 (9.5) 10.7 (10.6)
Year of heart disease diagnosis, %*
2004 or later 11.1* 17.3
2001–2003 19.9* 19.0
1998–2000 15.1* 14.7
1995–1997 13.4* 16.2
1992–1994 8.6* 7.7
1989–1991 9.4* 7.8
1986–1988 7.2* 5.3
1985 or earlier 15.3* 12.0
*p = 0.01 comparing HD respondents with and without type 2 diabetes mellitus. HD, heart disease; SHIELD, Study to Help Improve
Early evaluation and management of risk factors Leading to Diabetes.
Table 3 Method of diagnosis for HD and physician specialty diagnosing HD among SHIELD respondents
Method of diagnosis
HD without
diabetes (n = 973)
HD + type 2 diabetes
mellitus (n = 600)
During routine screening or blood test, % 19.4% 19.5%
Tested after having symptoms, % 48.3%* 54.0%
Tested during treatment for another health problem, % 14.7%* 22.2%
Specialty of physician making diagnosis of HD n = 819 n = 569
Cardiologist, % 63.0% 68.7%
Family doctor⁄general practitioner, % 31.6% 27.1%
Endocrinologist, % 0.5% 0.9%
Other (neurologist, emergency room physician, pulmonologist, surgeon), % 4.9% 3.3%
*p < 0.05. HD, heart disease; SHIELD, Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes.
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increased again in recent years (2004 or later); how-
ever, the trend was not signiﬁcant (p > 0.05) (Fig-
ure 3). The percentage of respondents with HD and
T2DM reporting routine screening or other health
problems as the method of diagnosis did not change
over time (p > 0.05) (Figure 2).
Specialty of physician who diagnosed HD
The majority of respondents with HD self-reported
that they received their HD diagnosis from their car-
diologist (63.0% and 68.7% in non-diabetes and
T2DM groups, respectively) (Table 3). A smaller per-
centage indicated their family doctor or general prac-
titioner as the physician diagnosing their HD (31.6%
and 27.1% in non-diabetes mellitus and T2DM
groups, respectively). Very few in either group
(< 1%) reported that an endocrinologist had diag-
nosed their HD. Approximately 5% and 3% reported
other physician specialties in the non-diabetes mell-
itus and T2DM groups, respectively. There was no
signiﬁcant difference between the groups in the
specialty of physician making the HD diagnosis
(p = 0.15). This pattern of physician specialty neither
changed signiﬁcantly over time nor did it differ sub-
stantially by respondent age group (p > 0.05).
.
Discussion
This SHIELD analysis showed that the majority of
respondents reported a diagnosis of HD based on
symptoms; 48–54% of individuals with or without
T2DM reported symptoms as the reason for the
diagnosis of HD. Symptoms-based diagnosis was
reported more frequently in the T2DM group, which
may suggest that the opportunity to diagnose HD
early (prior to symptoms) among this at-risk group
is being missed for some individuals. In particular,
the AHA⁄ADA scientiﬁc statement recommends risk
factor screening annually (lipids) or at every routine
diabetes visit (blood pressure) for those with T2DM
Figure 2 Method of HD diagnosis for SHIELD respondents with HD and no diabetes mellitus (n = 973). Respondents
were permitted to check multiple responses
Figure 3 Method of HD diagnosis for SHIELD respondents with HD and type 2 diabetes mellitus (n = 600). Respondents
were permitted to check multiple responses
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presenting for medical care until they have symp-
toms, resulting in a diagnosis of HD at an advanced
stage of the disease. In either situation, increased
educational efforts to promote awareness and screen-
ing of risk factors and detection of HD are war-
ranted. However, there is some evidence that routine
screening for HD is increasing in recent years among
individuals without T2DM. The proportion of
respondents with no diabetes mellitus reporting rou-
tine screening as the method of diagnosis increased
from 1998–2000 to 2006. Also encouraging is the
increase from 2001–2003 to 2006 for respondents
with T2DM who reported their HD diagnosis was
based on another health problem. This increase in
the proportion diagnosed as a result of being treated
for another health problem may be related to their
diabetes mellitus care and is a good opportunity for
identifying HD in this high-risk group. Yet, the
increases in diagnosis through routine screening or
other health problems were relatively small and not
signiﬁcantly different from the trend in prior years,
so additional awareness-raising and adoption of the
published guidelines are warranted, especially in light
of the high prevalence of risk factors among these
respondents.
Family practitioners often are the ﬁrst healthcare
providers an individual visits after experiencing
symptoms of any kind, which may explain why up
to one-third of respondents in this survey reported
having a family practitioner diagnose them with HD.
The majority of respondents, regardless of whether
they had T2DM or not, were diagnosed with HD by
a cardiologist. It is probable that these respondents
were referred to the cardiologist by their primary
care physician (or endocrinologist or emergency care
physician) for further evaluation, where the diagnosis
was ultimately made.
Findings from the SHIELD surveys also conﬁrm
that respondents with HD present with one or more
of the key risk factors associated with CHD and
CVD. For both HD respondents with and without
T2DM, the majority had dyslipidaemia and hyper-
tension and were overweight or obese. The T2DM
group reported higher obesity rates, which was
expected, as individuals with T2DM are more likely
to be overweight or obese (21). Of note, < 12% of
those with an HD diagnosis indicated that they were
current smokers in either group, which may indicate
increased awareness of smoking and its contribution
to CHD and CVD. However, it is not known
whether the individuals were smoking at the time of
their HD diagnosis. Only 15% of the non-diabetes
mellitus group and 9% of the T2DM group self-
reported that they were exercising regularly (highly
active), and there were more inactive individuals
with a self-reported diagnosis of HD and T2DM than
those with a self-reported diagnosis of HD without
diabetes mellitus, which may indicate that individuals
are not aware of the importance of exercise in reduc-
ing their HD risk (22).
National data indicate that the average age of
patients experiencing a myocardial infarction is
approximately 66 years for men and 70 years for
women (1). In the SHIELD study, respondents with
and without T2DM reported an average age at diag-
nosis of HD of 56–57 years, which might indicate
that these respondents are being diagnosed earlier,
possibly before their ﬁrst myocardial infarction. In
addition, signiﬁcantly more respondents with T2DM
were diagnosed in recent years (2001 or later) com-
pared with respondents without diabetes mellitus,
which may indicate greater awareness of the cardio-
vascular risk that diabetes mellitus poses, possibly
through the publication and adoption of the guide-
lines from AHA, ACC and NCEP.
This study provides evidence of the methods
employed for and the physician specialties diagnosing
HD in a large sample of respondents with a high
survey rate who are representative of the US popula-
tion. However, there are limitations to the study
that should be considered. Only a small percent-
age (5–8%) of those invited to participate in the
TNS NFO panel elect to do so, and those who parti-
cipate are accustomed to completing surveys, leading
to the possibility of selection bias. Household panels
tend to under-represent the very wealthy and very
poor segments of the population and do not include
military and institutionalised individuals, which are
shortcomings for most random sampling and clini-
cally based studies. Additionally, the determination of
HD, diabetes mellitus and risk factors was made
based upon self-report rather than clinical or labora-
tory measures for blood glucose, cholesterol and
hypertension. Recall of method of diagnosis by the
respondent also could potentially differ for recently
diagnosed respondents compared with respondents
given the diagnosis more than 15 years previously.
There may be potential for recall bias; however, the
trends for methods of diagnosis did not change
signiﬁcantly between 1992 and 2000, which may indi-
cate similar recall among those diagnosed 15–16 years
ago and those diagnosed 7–8 years ago. Recall bias
may potentially affect those diagnosed more than
15 years ago.
Conclusions
Despite increased knowledge and awareness of
the risk factors for CHD, many individuals are not
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fact that only a small percentage of SHIELD respon-
dents were diagnosed through screening indicates
that there is a missed opportunity to diagnose HD
during earlier, less severe stages of the disease. As
blood pressure and weight are evaluated at most
physician ofﬁce visits, medical providers already have
information on two key modiﬁable risk factors.
There is a need for improved targeted education
toward patients and physicians on reducing HD risk
before symptoms occur.
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